Exenatide pharmacokinetics in healthy Chinese subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 9, 2008, Pages 459-465

  Zhao, X ^a   Cui, Y M ^a   Zhou, Y ^a   Zhang, H L ^a   Yeo, K P ^b   Linnebjerg, H ^c   Tham, L S ^b   Kothare, P ^c   Teng, L L ^b   Mace, K ^c   Soon, D ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Chinese; Exenatide; Pharmaco kinetics

Indexed keywords

EXENDIN 4;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EVENING DOSAGE; FEMALE; GASTROINTESTINAL TOXICITY; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 52149111848     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46459     Document Type: Article

References (32)

1. Baron AD, Kim D, Weyer C. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord. 2002; 2: 63-82.
2. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2628-2635.
3. BYETTA prescribing information. [article online]; 2007. Available from http://pi.lilly.com/us/byetta-pi.pdf. Accessed 23 January 2008.
4. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab. 2006; 7: 367-374.
5. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 1998; 47: 764-769.
6. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999; 131: 281-303.
7. De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28: 1092-1100. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman MS, Schmitz O. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004; 53: 2397-2403.
8. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003; 26: 2929-2940.
9. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001; 281: E155-E161.
10. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002; 87: 1282-1290.
11. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992; 267: 7402-7406.
12. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003; 26: 2370-2377.
13. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004; 20: 411-417.
14. Fineman MS, Phillips L, Jaworowicz DJ, Cirincione B, Ludwig E, Taylor K, Kothare PA, Baron AD, Grasela T. Model-based evaluations to select and confirm doses in the clinical development of exenatide. Clin Pharm Ther. 2007; 81: S111. Abstract PIII-82.
15. Gu D, Reynolds K, Duan X, Xin X, Chen J, Wu X, Mo J, Whelton PK, He J. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia. 2003; 46: 1190-1198.
16. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999; 22: 403-408.
17. International Conference on Harmonisation. ICH topic E5(R1), Ethnic factors in the acceptability of foreign clinical data [article online]; 1998. Available from http://www.ich.org/LOB/media/MEDIA481.pdf. Accessed 23 January 2008.
18. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287: 360-372.
19. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083-1091.
20. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24: 275-286.
21. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 3082-3089.
22. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005; 62: 173-181.
23. Kothare PA, Soon DK, Linnebjerg H, Park S, Chan C, Yeo A, Lim M, Mace KF, Wise SD. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005; 45: 1032-1037.
24. Kothare PA, Uenaka K, Reddy S, Linnebjerg H, Yamamura A, Park S, Mace K, Fineman MS, Isaka Y. A comparison of exenatide pharmacokinetics (PK) between Japanese and non-Asian patients with Type 2 diabetes mellitus (T2DM). The AAPS Journal. 8[S2], Abstract W4076. 2006.
25. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004; 117: 77-88.
26. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman MS, Kim D. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technology & Therapeutics. 2005; 7: 467-477.
27. Reddy S, Park S, Fineman MS, Jay L, Carter M, Reynolds L, Sanburn N, Kothare PA. Clinical pharmacokinetics of exenatide in patients with type 2 diabetes. The AAPS Journal. 7[S2], Abstract M1285. 2005.
28. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006; 46: 1179-1187.
29. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes. 1995; 44: 1249-1258.
30. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000; 21: 697-738.
31. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997; 277: 925-926.
32. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002; 359: 824-830.